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ABSTRACT 29 
The human papillomavirus (HPV) life cycle is tightly linked to differentiation of the infected 30 
epithelial cell suggesting a sophisticated interplay between host cell metabolism and virus 31 
replication. Previously we demonstrated in differentiated keratinocytes in vitro and in vivo 32 
that HPV16 infection caused increased levels of the cellular SR splicing factors (SRSFs) 33 
SRSF1 (ASF/SF2), SRSF2 (SC35) and SRSF3 (SRp20). Moreover, the viral E2 transcription 34 
and replication factor that is expressed at high levels in differentiating keratinocytes could 35 
bind and control activity of the SRSF1 gene promoter. Here we reveal that E2 proteins of 36 
HPV16 and HPV31 control expression of SRSFs 1, 2 and 3 in a differentiation-dependent 37 
manner. E2 has the greatest trans-activation effect on expression of SRSF3. siRNA 38 
depletion experiments in two different models of the HPV16 life cycle (W12E  and NIKS16) 39 
and one model of the HPV31 life cycle (CIN612-9E) revealed that only SRSF3 contributed 40 
significantly to regulation of late events in the virus life cycle. Increased levels of SRSF3 are 41 
required for L1 mRNA and capsid protein expression. Capsid protein expression was 42 
regulated specifically by SRSF3 and appeared independent of other SRSFs. Taken together 43 
these data suggest a significant role of the HPV E2 protein in regulating late events in the 44 
HPV life cycle through transcriptional regulation of SRSF3 expression. 45 
  46 
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IMPORTANCE 47 
Human papillomavirus replication is accomplished in concert with differentiation of the 48 
infected epithelium. Virus capsid protein expression is confined to the upper epithelial layers 49 
so as to avoid immune detection. In this study we demonstrate that the viral E2 transcription 50 
factor activates the promoter of the cellular SRSF3 RNA processing factor. SRSF3 is 51 
required for expression of the E4^L1 mRNA and so controls expression of the HPV L1 52 
capsid protein. Thus we reveal a new dimension of virus-host interaction crucial for 53 
production of infectious virus. SRSF proteins are known drug targets. Therefore, this study 54 
provides an excellent basis for developing strategies to regulate capsid protein production in 55 
the infected epithelium and production of new virions. 56 
  57 
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 58 
INTRODUCTION 59 
 60 
Human papillomaviruses (HPVs) infect epithelia causing benign lesions or warts. For the so-61 
called “high risk” (HR) HPVs such as HPV type 16 (HPV16), the most prevalent HPV, 62 
persistent infection causes cervical and other anogenital lesions and head and neck lesions 63 
that may progress to cancer [1]. Although prophylactic vaccines against the most prevalent 64 
HR-HPVs are available, therapies are still required to treat infected individuals who are not 65 
vaccinated. A more comprehensive understanding of the HR-HPV replication cycle could 66 
help in the development of novel therapeutic approaches. 67 
 68 
The HPV16 life cycle is tightly linked to differentiation of the epithelium the virus infects [2]. 69 
Initial infection is within basal epithelial cells where the episomal viral genome is maintained 70 
at around 50-100 nuclear copies [3]. Differentiation of infected epithelial cells leads to 71 
activation of early, then late gene expression [4]. The viral replication and transcription 72 
factor, E2 is expressed at greatest levels in the mid to upper layers of the epithelium [5,6] 73 
where together with the viral DNA helicase, E1 it facilitates vegetative viral DNA replication 74 
leading to production of thousands of viral genome copies [7]. The viral late proteins, 75 
including the capsid proteins L1 and L2 are synthesized in the uppermost granular layer of 76 
the epithelium to encapsidate the newly replicated genomes [4]. This spatial restriction of 77 
production of the highly immunogenic capsid proteins is important as it avoids triggering an 78 
immune response as a result of low immune surveillance in the upper epithelial layers.  79 
 80 
Expression of virus capsid proteins is known to be controlled not only at the level of 81 
transcription initiation but also at various post-transcriptional levels including 82 
polyadenylation, alternative splicing, nuclear export, mRNA stability and translation [2,8–12]. 83 
Notably, at least thirteen mRNAs are produced late in the virus life cycle that contain open 84 
reading frames encoding the capsid proteins [10]. Seven mRNAs contain the L1 but not the 85 
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L2 open reading frame and six mRNAs contain both L1 and L2 open reading frames. 86 
Alternative splicing regulates the proportions of the various late mRNAs encoding the capsid 87 
proteins [12]. In particular, viral capsid protein L1 is thought to be encoded by an E4^L1 88 
mRNA produced by splicing from a splice donor site at the end of the E4 open reading frame 89 
to the splice acceptor site at the start of the L1 coding region while the L2 capsid protein is 90 
encoded by a read through L2L1 RNA [10]. 91 
 92 
Constitutive splicing is the process whereby introns are removed from pre-mRNAs and 93 
exons are spliced together to form a protein-coding mRNA. Alternative splicing is a 94 
mechanism used by mammalian and viral genomes to maximise coding potential [13,14]. A 95 
gene is transcribed to give a single primary transcript but from this precursor RNA (pre-96 
mRNA) different mature mRNA isoforms are produced by differential inclusion or exclusion 97 
of exons and introns. Each alternatively spliced mRNA isoform can encode a different 98 
protein. Alternative splicing is directly regulated by the following two classes of proteins, SR 99 
proteins (serine-arginine-rich splicing factors, SRSFs) and hnRNP proteins (heterogenous 100 
ribonucleoproteins) [15]. SR proteins can bind to exonic sequence enhancers (ESEs) to 101 
stimulate recognition of adjacent splice sites by the splicing machinery while hnRNP proteins 102 
recognise exonic splicing silencers (ESSs) to repress splice site utilisation [16]. Therefore 103 
the combinations of cis-acting ESEs and ESSs in open reading frames together with the 104 
relative concentrations of trans-acting SR and hnRNP proteins that can access these sites 105 
determine the ultimate mRNA isoforms produced from a single gene. 106 
   107 
Aside from splicing, SR proteins can potentially regulate other processes that control protein 108 
production from an mRNA including transcription elongation, polyadenylation, nonsense-109 
mediated decay, nuclear export mRNA stability, and translation [17].  There are nine 110 
classical SR proteins described, named SRSF1-9. Previous data have demonstrated the 111 
importance of a number of these proteins in production of HPV mRNAs [18]. SRSF1 112 
(SF2/ASF), SRSF3 (SRp20) and SRSF9 (SRp30c) have been shown to bind viral mRNAs in 113 
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the E4 open reading frame [19–22]. SRSF2 (SC35) and SRSF3 have been shown to control 114 
production of the viral E6 and E7 oncoprotein mRNAs [19,23]. Previous studies that have 115 
examined SR protein regulation of viral RNA splicing in tumour cells transiently expressing 116 
subgenomic reporter constructs have demonstrated that SRSF1 controls expression of early 117 
and late viral mRNAs [20,22] while SRSF3 can regulate BPV1 and HPV16 early and late 118 
gene expression [19]. SRSF9 can also control HPV16 late gene expression [21]. 119 
 120 
Previously we demonstrated in vitro and in vivo that HPV16 infection up-regulated 121 
expression of a specific subset of SR proteins in differentiating epithelial cells, these being 122 
the three smallest; SRSF1, SRSF2, and SRSF3, [24].  Subsequently we showed that the 123 
viral transcription factor E2 activated the SRSF1 promoter via its trans-activation domain 124 
[25]. Here we demonstrate that HPV16 E2 also specifically trans-activates the promoters of 125 
SRSF2 and SRSF3. We have extended the work to show that HPV31 E2 can also 126 
transcriptionally control SR protein expression in an epithelial differentiation-stage specific 127 
manner. siRNA depletion experiments were used to determine which HPV-regulated SR 128 
protein(s) was important for HPV16 late mRNA and capsid protein production. Data revealed 129 
that SRSF3 depletion resulted in significantly reduced levels of L1 protein suggesting that 130 
E2-regulated SRSF3 is required for capsid protein expression. SRSF3 was required for 131 
expression of the viral E4^L1 spliced mRNA but appeared to repress expression of the L2L1 132 
unspliced read through RNA.  Taken together, these data indicate that the E2 protein links 133 
the viral replication cycle to epithelial differentiation via SRSF3, a key cellular regulator of 134 
HR-HPV gene expression. 135 
  136 
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EXPERIMENTAL 137 
 138 
Cell lines 139 
 140 
W12E cells are non-tumour cervical epithelial cells (clone 20863: [26]) that if maintained at 141 
low passage (<17) contain 50-100 nuclear episomal copies of the HPV16 genome. NIKS16 142 
cells are normal immortalised keratinocytes (NIKS) stably transfected with the HPV16 143 
genome. Clone 2L maintains episomal HPV16 genomes [27]. CIN612-9E cells are cervical 144 
kerationcytes containing episomal HPV31 genomes [28]. All three lines form tissues in raft 145 
culture that mimic a low grade cervical lesion. W12E, NIKS, NIKS16 and CIN612-9E cells 146 
were cultured in E-medium and differentiated as described (2x105 cells per 10 cm plate) on 147 
mitomycin C-treated J2 3T3 mouse fibroblasts [10,26]. Cells were differentiated by growing 148 
to high density in the presence of 1.88 mM Ca2+ as previously described [26]. The 3T3 cells 149 
were grown in DMEM with 10% donor calf serum.  Prior to harvesting for RNA or protein 150 
preparation, 3T3 cells were removed by trypsinisation and cells layers washed twice with 151 
PBS. U2OS osteosarcoma cells and U2OS clones stably expressing HPV16 E2 (U2OSA4, 152 
U2OSB1) were cultured in DMEM with 10% foetal calf serum. All cells were maintained 153 
under humidified 5% CO2 95% air at 37°C. 154 
 155 
Cell transfection and siRNA depletion 156 
Cells were seeded at 2x105 per 10 cm dish and grown for 4 days on  mitomycin C-treated J2 157 
3T3 mouse fibroblasts as describe above. At day 4 fibroblasts were removed by brief 158 
trypsinisation. Keratinocytes were washed  twice with PBS and transfected with plasmids 159 
using Lipofectamine 3000 according to the manufacturer’s protocol. 8 h after transfection 160 
freshly prepared mitomycin C-treated J2 3T3 mouse fibroblasts were added back to the 161 
keratinocyte cultures in fresh E-medium. After 72 hours cells were harvested into 400 µl 162 
protein loading buffer (125 mM Tris (pH 6.8), 4% SDS, 20% glycerol, 10% mercaptoethanol 163 
and 0.006% bromophenol blue, fresh protein inhibitor cocktail (Roche, UK). Lysates were 164 
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passed through a 21 gauge needle 15 times then sonicated in a sonibath for 3 x 30 sec.  165 
Cells were seeded at 2x105 per well in a six well plate 24 h prior to transfection in antibiotic-166 
free medium.  siRNA (10 nM) and Lipofectamine RNAi MAX (Invitrogen) were diluted in Opti-167 
MEM serum-free medium (Invitrogen). Cells were transfected for 48 h according to the 168 
manufacturer’s protocol. siGENOME SMART pools (consisting of four siRNAs designed to 169 
minimise off-target effects) specific for each of the SRSFs tested were purchased from 170 
Dharmacon. Transfection efficiencies as calculated by co-transfection with siGLO 171 
(Dharmacon) or a GFP expression plasmid were between 70-80%.  172 
 173 
Cloning the SRSF3 expression vector 174 
pEGFPSRp20 was a gift of Dr R. Sandri-Goldin. The insert fragment from pEGFPSRp20 175 
was cleaved out using BamHI/EcoRI restriction digest. The fragment was then inserted using 176 
the same sites into pcDNA3.1 to give plasmid pcDNA3.1SRSF3. 177 
 178 
Cloning the SRSF promoters 179 
SRSF promoter regions were amplified from HeLa cell DNA. For SRSF1pr the forward 180 
primer was 5’-GATCCTCGAGGTTACGGTTCTCACATCCATTTTGC-3’ and the reverse 181 
primer was 5’- GTGCAAGCTTCTCCCGCGGCCCCTCCAAAATG-3’ (amplifying nucleotides 182 
-886 to +143 relative to the transcription initiation site at +1). For SRSF2pr the forward 183 
primer was 5’-GGGTGGTACCGTCAGCTCTCCTCGGGGCGAAG-3’ and the reverse primer 184 
was 5’-GTACAAGCTTTCTCAGGCAGTTGCCTTCCGCG-3’ (amplifying nucleotides -985 to 185 
+96 relative to the transcription initiation site at +1). For SRSF3pr the forward primer was 5’-186 
GATCGGTACCGCGGCTCTGTCTTCGTAAGGG-3’ and the reverse primer was 5’-187 
GTGCAAGCTTCTCTCACTCACCCGGCGTCC-3’ (amplifying nucleotides -720 to +81 188 
relative to the transcription initiation site at +1). For SRSF7pr the forward primer was 5’-189 
CATCCTCGAGACCAACTAGGCCTGCTTTCC-3’ and the reverse primer was 5’-190 
GTGCAAGCTTAAACAGCCAAGAAACGACGC-3’ (amplifying nucleotides -1036 to + 69) 191 
relative to the transcription initiation site at +1). Nucleotides in bold italics indicate the Xho I 192 
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of HinD III restriction enzyme sites that were used for cloning. A four base pair overhang was 193 
added to the end of each primer sequence to facilitate restriction enzyme cleavage. PCR 194 
was performed with High Fidelity Platinum® Taq polymerase (Invitrogen). Single amplicons 195 
were obtained with the correct theoretical length. PCR products were ligated into pGL3 basic 196 
vector (Promega) and transformed into super competent E. Coli DH5α (Invitrogen). Insert 197 
sequences of clones obtained were confirmed by DNA sequencing. 198 
Transcription assays 199 
U2OS and U2OS clones A4 and B1 cells that stably express HPV16-E2 [29]) were seeded in 200 
10mm well plates at 1x105 cells per well without antibiotics 24 h prior to transfection. 201 
Transfections were carried out using Lipofectamine 2000 (Invitrogen). An EGFP expression 202 
vector (pMAXEGFP) was used as a transfection efficiency control using. Protein was 203 
extracted 48-72 h post-transfection as follows. Cells were washed twice in ice cold PBS after 204 
the removal of the culture medium.  NP40 lysis buffer (0.5% NP40, 150mM NaCl, 50mM Tris 205 
HCl pH 8) with protease (Roche Diagnostics) and phosphatase (Roche Diagnostics) 206 
inhibitors was added to the cells and the cells scraped into the buffer on ice.  The lysed cells 207 
were transferred to a 1.5ml eppendorf tube and incubated on ice for 30 min with periodic 208 
vortexing.  The extracts were centrifuged at 10000g for 10 min and the supernatant was 209 
subsequently stored at -80°C. A luciferase assay system (Promega) and a GloMax–Multi 210 
Detection System luminometer were used to detect luciferase activity according to 211 
manufacturer’s instructions. Samples were normalized by protein concentration. At least 3 212 
independent experiments were performed. 213 
 214 
Cloning the HPV31 genome E2:I73L mutant 215 
The I73L mutation in the HPV31 genome was created using the QuickChange XL site 216 
directed mutagenesis kit (Agilent) using the plasmid pLit-HPV31 as template and the primers 217 
5'GCCAAAGCCT TACAAGCTcT TGAACTACAA ATGATGTTGG3' and 5'CCAACATCAT 218 
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TTGTAGTTCA AgAGCTTGTA AGGCTTTGGC 3' according to the manufacturer's 219 
directions. Primary human foreskin keratinocytes were transfected with recircularized HPV31 220 
genomes and expanded following drug selection as previously described [30]. 221 
 222 
Western blotting 223 
Cells were scraped into protein-loading buffer (125 mM Tris (pH 6.8), 4% SDS, 20% 224 
glycerol, 10% mercaptoethanol and 0.006% bromophenol blue with fresh protein inhibitor 225 
cocktail (Roche, UK)). Lysates were passed through a 21 gauge needle 15 times then 226 
sonicated in a sonibath for 3 x 30 sec.  Subsequently 10 µg protein (or 5, 10 20 µg where 227 
indicated) was resolved by polyacrylamide gel electrophoresis using NOVEX precast 4-12% 228 
gradient gels (Invitrogen) then transferred to nitrocellulose membrane using an i-blotter 229 
(Invitrogen).  The membrane was preincubated for 1 h at room temperature with 5% dried 230 
milk powder in PBS-0.1% Tween, before overnight incubation at 4ºC with diluted primary 231 
antibody in PBS-Tween, 1% dried milk powder. The following antibodies were used: SRSF1 232 
(clone 96) (Invitrogen, 32-4500) 1:1000. SRSF2 (BD Pharmingen, 556363) 1:250. SRSF3 233 
(clone 7B4) (Invitrogen, 33-4200) 1:250. SRSF7 (clone 98) gift of Dr James Stevenin 234 
(IGBMC, Strasbourg, France) 1:100. GAPDH (clone 6CS) (Biodesign International, 235 
H86504M) 1:5000. Involucrin (Sigma 19018) 1:1000. HPV16 E2 (clone TVG261) (Abcam 236 
ab17185) 1:250 and HPV L1 (clone K1H8) (Dako M3528). Mab104  (used neat) detects a 237 
phosphoepitope on SRSFs 1-6) (ATTC hybridoma supernatant). Because SRSFs1 and 2 238 
have a similar apparent molecular mass on SDSPAGE, as well as probing with Mab104, we 239 
also probed blots with specific monoclonal antibodies against these SR proteins as above   240 
Horseradish peroxidase (HRP)-conjugated secondary antibodies (Pierce-ECL) were diluted 241 
1:2000 in PBS-Tween and incubated for 1 h. Blots were developed using Pierce enhanced 242 
chemi-luminescence (ECL) kit and exposed to Kodak X-OMAT film. Blots were quantified by 243 
scanning at 300 dpi and image analysis using Image J. 244 
 245 
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Immunohistochemistry 246 
Archival paraffin-embedded cervical biopsy samples were obtained with ethical permission 247 
(Glasgow Royal Infirmary: RN04PC003). Diagnosis was made by a gynaecological 248 
pathologist. HPV presence was confirmed by PCR. Immunohistochemistry was carried out 249 
by the University of Glasgow Veterinary Diagnostic Services. SRSF3 antibody (clone 7B4) 250 
(Invitrogen, 33-4200) was used at a dilution of 1:100 251 
 252 
RNA extraction 253 
Cells were scraped into TRIzol reagent (Invitrogen) and total RNA was extracted according 254 
to the manufacturer’s protocol.  Polyadenylated RNA was isolated using an oligo-dT-based 255 
mRNA extraction kit (Oligotex, Qiagen) according to the manufacturer’s instructions. DNA 256 
was removed from all RNAs using the Promega RQ1 DNase kit according to the 257 
manufacturer’s instructions. DNase-treated RNA was reverse transcribed using the 258 
Superscript III kit (Invitrogen) according to the protocol provided.   259 
 260 
PCR 261 
cDNA was amplified using 200 nM primers, 200 µM dNTPs, 1.5 mM MgCl2 and 2 units Taq 262 
polymerase (Invitrogen). Primers for E4^L1 amplification were E4 forward (nts 3518-3540) 263 
5’-GTTGTTGCACAGAGACTCAGTGG-3’ matched with L1 reverse (nts 6918-6997) 5’-264 
GACAAGCAATTGCCTGGGTTAC-3’. Primers for L2L1 amplification were L2 forward (nts 265 
5465-5475) 5-GTATCAGGTCCTGATATACCC-3’, matched with L1 reverse B (nts 5690-266 
5669) 5’-TACTGGGACAGGAGGCAAGTAG-3’, GAPDH forward 5’- 267 
TCCACCACCCTGTTGCTGTA-3’; GAPDH reverse 5’- ACCACAGTCCATGCCATCAC-3’. 268 
PCR products were separated on a 6% acrylamide gel and post-stained with ethidium 269 
bromide.  270 
 271 
 272 
 273 
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qPCR 274 
cDNA was amplified using an Applied Biosystems 7500 qPCR machine.  The Stratagene 275 
Brilliant qPCR mastermix was used for qPCR reactions. cDNA (100ng) was amplified in 276 
each reaction in triplicate and three different experiments were performed. Reaction mixes 277 
(25 µl) contained 1xMastermix (Stratagene), 900 nM primers, 100 nM probe, 300 nM 278 
reference dye (Stratagene). E4 forward primer (nts 3594-3615) 5’-279 
CTGTAATAGTAACACTACACCC-3’ E4^L1 probe (nts 3620-3631:5637-5656) 5’-280 
TACATTTAAAAGTGTCTCTTTGGCTGCCTAG -3’. L2 forward primer (nts 5547-5569) 5’-281 
CAATTATTGCTGATGCAGGTGAC-3’, L2L1 probe (nts 5600-5622) 5’-282 
CGAAAACGACGTAAACGTTTACC -3’. L1 reverse (nts 5690-5669) 5’-283 
TACTGGGACAGGAGGCAAGTAG-3’. The amplification protocol was 95 oC for 15 sec, 50oC 284 
for 60 sec for 40 cycles. Expression was quantified using ΔΔCt relative to GAPDH values. 285 
  286 
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RESULTS 287 
 288 
 289 
HPV E2 regulates the promoters of the genes encoding SRSF1-3 290 
Using cell line models of epithelial differentiation and HPV infection and backed up by data 291 
from virus-infected patient tissue, we and others have demonstrated that SRSF1 (SF2/ASF) 292 
SRSF2 (SC35) and SRSF3 (SRp20) are specifically upregulated in HPV-infected, 293 
differentiated epithelial cells [24,25,31,32]. For SRSF1, we showed previously that HPV16 294 
E2 controlled the promoter of the SRSF1 gene by interacting within a region from -565 to -295 
363 nts with respect to the transcription initiation site (this was originally named -689 to -482 296 
in our previous paper [25] according to the numbering of a previously sequenced version of 297 
the SRSF1 promoter). Transcription activation was through the E2 trans-activation domain 298 
[25]. E2 was only able to trans-activate the SRSF1 promoter in the A4 clone of the 299 
osteosarcoma cell line U2OS that stably expresses low E2 levels (Figure 1A) [25, 29]. We 300 
proposed previously that E2 may begin to trans-repress the SRSF1 promoter at 301 
higher concentrations as it has been shown to do for the BPV4 long control region 302 
promoter [25]. To examine whether E2 also controlled expression of the genes encoding 303 
the other two SR proteins, SRSF2 and SRSF3, both of which are upregulated in HPV-304 
infected cells, we cloned their gene promoters into luciferase expression (pGL3-luciferase) 305 
vectors for transcription analysis. The SRSF1 promoter (previously assayed in 306 
chloramphenicol acetyl transferase (CAT) construct) was cloned in the same vector in order 307 
to use as a known E2-regulated control. The promoter for SRSF7 (9G8) was also cloned and 308 
analysed in order to compare an SRSF family member that we have shown is not 309 
upregulated during differentiation of HPV-infected cervical epithelial cells [24]. A non-SR 310 
protein promoter control, the hTERT promoter whose expression is down regulated by HPV 311 
E2 [33], and a pGL3 empty vector with no promoter sequence was also used. U2OS 312 
subclones A4 and B1 , stably express different amounts of HPV16 E2 protein: A4 expresses 313 
low and B1 expresses high levels (Figure 1A) [25,29].  Transient transfections of the different 314 
luciferase expression vectors were performed in U2OS, U2OSA4 and U2OSB1 cells. An 315 
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EGFP expression vector was co-transfected in each transfection experiment in order to 316 
normalise transfection efficiency. Figure 1B shows quantification of luciferase expression 317 
from the different promoters indicated on the X-axis. Control transfections of the 318 
promoterless pGL3 vector showed very low luciferase activity (pGL-3 empty). hTERT 319 
promoter activity  was low in all the experiments. This is due to U2OS cells displaying low 320 
telomerase activity [34]. Despite the low levels of reporter gene expression some decrease 321 
was detected in the U2OSB1 cell line that expresses higher levels of E2 as expected [33]. 322 
Similar to what we reported previously, the SRSF1 promoter was trans-activated by E2 323 
protein in the U2OSA4 cell clone which expresses low levels of HPV16 E2. However, the 324 
higher levels of E2 expressed by the U2OSB1 cell clone did not upregulate the SRSF1 325 
promoter confirming our previous data [25]. The SRSF2 promoter also showed a small but 326 
statistically significant upregulation by HPV16 E2 protein. Under control of the SRSF2 327 
promoter, luciferase activity was increased 1.35-fold in U2OSA4 cells and 1.24-fold in 328 
U2OSB1 cells (p<0.05). However, a greater increase in activity of the SRSF3 promoter than 329 
that observed for SRSF1 and SRSF2 in the presence of E2 was observed. The basal activity 330 
of the SRSF3 promoter in U2OS cells was lower than either the SRSF1 or 2 promoters and 331 
HPV E2 protein gave a greater trans-activation response, showing a larger absolute 332 
difference in fold change in luciferase activity.  Luciferase activity was increased 2.93-fold in 333 
U2OSA4 cells and 2.69-fold in U2OSB1 cells (p<0.001) (Figure 1B).  In contrast to the 334 
repressive effect seen on SRSF1 promoter activity, high levels of E2 expression did not 335 
abrogate the trans-activation of the SRSF3 promoter. The SRSF7 promoter is not controlled 336 
by HPV16 infection [24] and showed no statistically significant change in activity in the 337 
presence of E2 demonstrating that the E2-mediated up-regulation of SRSF1-3 is specific 338 
(Figure 1B). 339 
 340 
Differentiation of HPV31-positive keratinocytes increases SRSF1-3 levels. 341 
W12 cells are cervical epithelial cells derived from a patient with an HPV16-positive low 342 
grade cervical lesion [35]. Cells of the non-tumour subclone W12E (clone 20863), when 343 
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maintained at low passage (p>17), contain around 50-100 episomal copies of the HPV16 344 
genome [26,35]. W12E cells can be induced to differentiate to keratinocytes that express 345 
markers of terminal differentiation [36], viral late mRNAs and late proteins [10] by culturing to 346 
high density in the presence of 1.88 mM Ca2+. Previously we showed that a subset of SRSF 347 
proteins, including SRSF1, 2 and 3, were upregulated upon differentiation of W12E cells 348 
[24]. To determine if control of SRSF expression during epithelial differentiation was 349 
associated with other HR-HPV infections we examined SR protein levels in HPV31-infected 350 
CIN612-9E cervical epithelial cells [28]. CIN612-9E cells were established from an HPV31-351 
infected low grade cervical lesion and contain episomal HPV31 viral genome copies. 352 
CIN612-9E cells can also be induced to differentiate in culture using the same protocol as for 353 
W12 cells (by culturing to high density in the presence of 1.88 mM Ca2+) to express viral late 354 
mRNAs and synthesise virions [37, 38] ]. Monoclonal antibodies against SRSF1, SRSF3 and 355 
SRSF7 perform well in western blotting. However, to detect the remainder of the SR proteins 356 
we used Mab104 that detects a phosphoepitope on most of the classical SR proteins 357 
(SRSF1, 2, 4, 5 and 6). Therefore, in Figure 2A detection of SRSF1 is shown both with 358 
Mab104 and the SRSF1-specific antibody Mab96. Semi-quantitative western blot analysis of 359 
protein titrations (5, 10, 20 µg) showed that levels of SRSF1, 2 and 3, were higher in 360 
differentiated compared to undifferentiated HPV31-positive cells (Figure 2A), similar to what 361 
was found in W12E cells [24].Unlike W12E cells, CIN612-9E cells expressed SRSF4 362 
(SRp75) whose levels also increased upon differentiation. Levels of SRSF5 (SRp40) and 363 
SRSF6 (SRp55) increased slightly upon differentiation.  Levels of SRSF7 did not change 364 
significantly. Cell differentiation was revealed by detection of increased levels of the 365 
epithelial differentiation marker involucrin in the differentiated keratinocytes (Figure 2A). 366 
 367 
The E2 transactivation domain is required for control of SRSF1-3 levels. 368 
The data support the hypothesis that HR-HPV E2, which is expressed at highest levels in 369 
differentiating HPV-infected epithelial cells [5,6], controls expression of SR proteins. To test 370 
this directly, we compared levels of SR proteins in normal foreskin keratinocytes (NFKs) 371 
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stably transfected with wild type HPV genomes or with genomes containing an inactivating 372 
point mutation in the trans-activation domain of E2. HPV16 genomes containing such a 373 
mutant cannot be maintained episomally in keratinocytes [39]. However, keratinocytes 374 
containing HPV31 genomes with this mutation are available (mutant E2:I73L) [30]. If E2 375 
trans-activated the SRSF1-3 promoters there would be reduced levels of the proteins in 376 
these keratinocytes. Western blot quantification indeed revealed decreased levels of 377 
SRSF1-3 in the keratinocytes expressing the mutant E2 protein compared to keratinocytes 378 
expressing wild type E2 but there was no change in levels of SRSF7 as expected as it is not 379 
regulated by E2 (Figure 2B). There were similar viral genome copy numbers in E2 wt and 380 
E2:IL73 NFKs (data not shown). Figure 2C shows levels of E2 protein in each NFK line. 381 
Comparing with levels of GAPDH, there were similar levels of E2 protein expressed in E2wt 382 
compared to E2:IL73 cells (Figure 2C, lanes 3 & 4). The NFK E2wt and E2:IL73 protein 383 
extracts used in Figure 2B were prepared from differentiated NFK clones because both 384 
expressed involucrin, a marker of epithelial differentiation (Figure 2C, lanes 3 & 4)). Both 385 
E2wt and E2:IL73 NFKs clearly expressed more involucrin than undifferentiated HPV31-386 
positive CIN6129E cells (Figure 2C, lanes 2) and levels were almost as high as fully 387 
differentiated CIN6129E cells (Figure 2C, lanes 1). Levels of SRSF1 in the E2:I73L 388 
expressing cells were 52% (±3.2)% of wild type while SRSF2 and 3 were 31% (±6.5)% and 389 
29% (±5.0)% of wild type respectively (Figure 2D). These data indicate that E2 trans-390 
activates the SRSF gene promoters to control expression of SRSF1-3 proteins in infected 391 
epithelial cells. E2:I73L mutant HPV31 genomes express around 80% less late mRNA than 392 
wild type genomes [30] but whether this leads to reduced L1 protein expression has not 393 
been tested. In accordance with the reported change in late mRNA production, western 394 
blotting revealed that there was a reduction of around 75% in L1 protein expression from 395 
E2:I73L genomes compared to E2 wild type genomes (p<0.01) (Figure 2E). Our data 396 
suggest that HR-HPV E2 upregulates expression of SR proteins 1, 2 and 3 in infected, 397 
differentiated keratinocytes 398 
 399 
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SRSF3 controls expression of the HPV16 L1 capsid protein in differentiated 400 
keratinocytes. 401 
E2-mediated upregulation of cellular SR proteins 1-3 in differentiated infected epithelial cells 402 
could indicate that increased levels of these RNA processing proteins are required for 403 
completion of the viral replication cycle. Therefore we next determined which of the 404 
differentiation stage-specific controlled SR proteins controlled HPV capsid protein 405 
expression during the HPV life cycle in differentiating keratinocytes. For these experiments 406 
we used both the HPV16 infected W12E life cycle model we had used previously [24] and a 407 
second model of the HPV16 infectious life cycle (NIKS16) to corroborate our data with W12 408 
cells. NIKS16 cells are normal immortalised foreskin keratinocytes (NIKS) stably transfected 409 
with episomal HPV16 genomes [27]. If used at low passage, NIKS16 clone 2L stably 410 
maintains episomal genomes. Like W12E and CIN612 9E cells they can differentiate in 411 
monolayer culture and display a CIN1-like phenotype in organotypic raft culture [27]. 412 
Differentiation of W12E,  NIKS16 and the parental NIKS cells can be induced by culturing in 413 
1.88 mM Ca2+ to high density [10,26]. At the end of the differentiation protocol between 75-414 
85% of NIKS or NIKS16 cells expressed the differentiation marker involucrin  similar to that 415 
observed with W12E cells [10]. Using Mab104 that simultaneously detects SRSFs1, 2, 4, 5 416 
and 6 and antibody 7B4 that detects specifically SRSF3, semi-quantitative western blotting  417 
of 5, 10, 20 μg HPV-negative NIKS protein extracts revealed very little change in levels of 418 
SR proteins upon differentiation, similar to what we observed previously using HPV-negative 419 
HaCaT cells [25] (Figure 3A). However, semi-quantitative western blotting  of 5, 10, 20 μg 420 
HPV16-positive NIKS16 protein extract revealed a pattern of change in SRSF expression 421 
between undifferentiated and differentiated NIKS16 cells similar to that observed for W12E 422 
[24] and CIN612-9E cells (Figure 2A). Figure 3B shows that levels of SRSFs1, 2 and 3 were 423 
higher in differentiated NIK16 cells. Levels of SRSF4 and 6 also appeared to increase 424 
slightly while SRSF5 and 7 levels (SRSF7 was detected with specific monoclonal antibody 425 
clone 98) did not change. Quantification of changes in SRSF3 levels between 426 
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undifferentiated and differentiated HPV-negative NIKS cells revealed a reduction of 30% 427 
upon differentiation (Figure 3C). In contrast, SRSF3 levels increased four-fold upon 428 
differentiation of HPV16-positive NIKS16 cells similar to the increase in SRSF3 levels we 429 
quantified in W12 cells previously  [24] (Figure 3D). Immunohistochemistry staining of 430 
normal cervical epithelium revealed staining in the basal layer cells and some in the 431 
suprabasal layers (Figure 3E). Immunohistochemistry staining of a representative low grade 432 
cervical lesion revealed that while more cells in the basal epithelial layers stained positive for 433 
SRSF3 compared to cells in the upper layers, the intensity of staining of cells in the mid to 434 
upper layers was strong indicating high levels of SRSF3 expression (Figure 3F). 435 
 436 
Having demonstrated that NIKS16 cells control expression of SRSFs1, 2, and 3 in a similar 437 
manner to W12E and CIN612-9E cells [24], these SR proteins were depleted using siRNA in 438 
NIKS16 keratinocytes. SRSFs 5 and 7 were also depleted as controls for SR proteins that 439 
are not regulated by E2 or HPV infection. Figure 4A shows that levels of each of the SR 440 
proteins were significantly reduced by their respective siRNAs. SRSF1, 2 and 5 were 441 
detected with Mab104 (top panel) that detects most of the classical SR proteins. The second 442 
panel from the top shows detection of SRSF1 using specific antibody Mab96. A second 443 
panel showing SRSF1 and 2 detected together is included as the third panel down from the 444 
top because SRSF2 depletion is not clearly seen in the top panel. The bottom two panels 445 
show SRSF3 detected by specific antibody 7B4 and SRSF7 detected by specific antibody 446 
clone 98. Levels of L1 protein were assessed as a marker of late events in the virus life cycle 447 
in the SRSF-depleted cells by western blotting with and HPV L1 antibody. L1 was expressed 448 
in differentiated (Figure 4B lane 2) but not in undifferentiated (Figure 4B lane 1) NIKS16 cells 449 
as expected from data on raft cultures of this line [27]. Differentiation was assessed by 450 
increased expression of the epithelial differentiation marker involucrin (Figure 4B compare 451 
lanes 1 and 2). There was no significant change in levels of L1 protein in differentiated 452 
NIKS16 cells when either SRSF1, 2, 5 or 7 were depleted. However, depletion of SRSF3 453 
(Figure 4B, lane 5) caused a significant decrease in L1 protein expression. Quantification of 454 
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three separate experiments showed that loss of SRSF3 caused a decrease of 53% ±11% 455 
(p<0.05) in L1 protein expression in differentiated NIKS16 cells (Figure 4C). 456 
 457 
Next we confirmed the SRSF3 regulation of L1 expression in the W12E model of the HPV16 458 
life cycle. SRSF1 was used as a control SR protein as this did not significantly affect the 459 
levels of HPV16 L1 protein in NIKS16 cells (Figures 4B and 4C). SRSF1 and SRSF3 were 460 
successfully depleted using specific siRNAs in undifferentiated (W12U) and differentiated 461 
(W12D) W12E cells (Figure 5A). Involucrin expression was higher in the differentiated cell 462 
population as expected (Figure 5A, lanes 4-6). No L1 protein expression was detected in 463 
undifferentiated W12 cells but high levels of L1 protein were detected in differentiated W12E 464 
cells (Figure 5A lane 4). Depletion of SRSF1 had a small reduction effect on L1 protein 465 
expression in the differentiated cells (Figure 5A, lane 5) but, consistent with the data using 466 
NIKS16 cells, SRSF3 depletion reduced L1 protein levels significantly (Figure 5A, lane 6). 467 
Quantification of data from three separate experiments showed that L1 protein levels were 468 
reduced by 55% ±11% (p<0.05) in differentiated W12E cells (Figure 5B). 469 
 470 
If SRSF3 depletion in differentiated NIKS16 cells results in loss of L1 expression then 471 
overexpression of SFSF3 in undifferentiated NIKS16 cells might activated L1 expression. To 472 
test this we transfected undifferentiated NIK16 cells with an expression construct for SRSF3 473 
(pcDNA3.1SRSF3). Cells were maintained at low cell density in medium with low calcium 474 
concentrations over the course of the experiment to minimise differentiation [26]. 72 hours 475 
following transfection cells were harvested and protein lysates were prepared. Western blot 476 
analysis revealed that cells transfected with vector alone did not express L1 protein (Figure 477 
5C, lane 2). In contrast, cells transfected with the SRSF3 expression construct showed some 478 
L1 expression (Figure 5C, lane 3) but not to the level detected in fully differentiated NIKS16 479 
cells  (Figure 5C, lane 1). The transfected NIKS16 cells had not been induced to differentiate 480 
because levels of involucrin differentiation marker were low in the transfected cells (Figure 481 
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5C, lanes 2 & 3) compared to the fully differentiated NIKS16 cell control (Figure 5C, lane 1). 482 
Taken together the data reveal that SRSF3 is a key regulator of HPV16 L1 protein levels. 483 
 484 
SRSF3 depletion results in loss of the E4^L1 spliced RNA 485 
SRSF3 can regulate mRNA expression at a number of different levels [40] and it is known to 486 
be a master regulator of alternative splicing [41]. Alternative splicing is a key control 487 
mechanism of HPV gene expression. HPV L1 capsid protein is thought to be expressed from 488 
an E4^L1 spliced transcript (RNA B) but may also be expressed from an E1^L1 (RNA A) or 489 
the bicistronic L2L1 transcript (RNA C) (Figure 5A) [10,42]. Therefore, we examined if levels 490 
of any of these mRNAs were affected by SRSF3 depletion during the HPV16 life cycle. We 491 
mock-depleted or siRNA-depleted SRSFs 1 and 3 in W12E cells and allowed the cells to 492 
differentiate. siRNA treatment successfully depleted levels of SRSF1 and 3 (Figure 5B). We 493 
used primer pairs to PCR amplify across splice junctions E1^L1 and E4^L1 or across the 494 
junction of the open reading frames in the read-through L2L1 mRNA. E1^L1 proved very 495 
difficult to detect indicating that it is an mRNA present at very low levels in HPV16-positive 496 
keratinocytes. In viral late mRNAs, the end of the E4 open reading frame contains a splice 497 
donor site at nt 3632 that allows splicing to the L1 splice acceptor site at nt 5639. E4^L1 498 
mRNAs were detected readily. Compared to the effect of SRSF1 depletion that has only a 499 
small effect on L1 protein production, SRSF3 depletion caused a remarkable decrease in 500 
levels of late mRNA E4^L1 (RNA B) in differentiated W12E cells (Figure 5C, lane 6). SRSF1 501 
depletion did not alter production of this RNA (Figure 5C, lane 4). In contrast, depletion of 502 
SRSF1 or SRSF3 appeared to increase the levels of the L2/L1 bicistronic mRNA (RNA C) 503 
(Figure 5C, lower panel, lanes 4 and 6). Levels of GADPH did not change upon SRSF1 or 504 
SRSF3 depletion. qRT-PCR analysis using previously published probe/primer sets [43] 505 
confirmed that E4^L1 mRNA levels were reduced significantly upon SRSF3 depletion in 506 
differentiated cells (Figure 5D) while the bicistronic L2L1 mRNA levels increased when either 507 
SRSF1 (2.0-fold) or SRSF3 (1.7-fold) were depleted (Figure 5E).  Taken together these data 508 
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suggest that SRSF3 can control production of L1 capsid protein via enhancing expression of 509 
the E4^L1 mRNA. 510 
 511 
 512 
  513 
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DISCUSSION 514 
 515 
Focusing on the paradigm SR protein SRSF1 we demonstrated previously that E2 bound the 516 
SRSF1 promoter and its trans-activation domain was essential for upregulation of SRSF1 517 
transcription [25]. Here we have shown that E2 transcriptionally activates the genes 518 
encoding not only SRSF1 but also SRSF2 and 3.  The SRSF3 promoter displayed the 519 
highest level of transactivation in our transcription assays. E2 regulated the SRSF3 promoter 520 
in a dose-dependent manner. This is different to the SRSF1 promoter that we found was 521 
activated by low levels but repressed by high levels of E2 (this manuscript, [25]). We do not 522 
yet understand how E2 transactivates the SRSF promoters because similar to what we have 523 
found for the SRSF1 promoter [24] the SFSR2 and 3 promoters do not contain a cognate E2 524 
binding site. In silico analysis of the proximal promoter sequences of SRSF1-3 revealed that 525 
they are each predicted to bind the E2-interacting factors Sp1 and cEBP (data not shown) 526 
but it remains to be tested if E2 binds and transactivates via these proteins and if other 527 
factors are also involved. It is even possible that the array of cellular transcription factors that 528 
control each promoter may be different and mediate different transcriptional responses to 529 
E2. SRSF7 was used in the transcription assays as a control promoter as it is not regulated 530 
by E2 but we did not clone and test E2 control of other SRSFs. Therefore we cannot 531 
conclusively rule out the possibility that E2 controls the expression of additional SRSF 532 
proteins. However, our data clearly reveal that the cellular SRSF1, 2 and 3 genes are 533 
upregulated by HPV16 E2. This is the first reported cloning of these SRSF promoters. 534 
 535 
Semi-quantitative western blotting experiments revealed a similar profile of changes in SRSF 536 
protein levels upon differentiation of HPV16-positive W12E cells [24], NIKS16 cells (Figure 537 
3A) and the HPV31-positive CIN612-9E cells. This allowed us to test the mechanism of E2 538 
control of the SRSF promoters by comparing levels of the SRSF proteins in normal foreskin 539 
keratinocytes stably transfected with a wild type HPV31 genome or a genome containing a 540 
single inactivating point mutation in the E2 transactivation domain [30]. There was a 541 
significant decrease in expression of SRSFs1-3 in keratinocytes expressing the point mutant 542 
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E2. These data support our hypothesis that HR-HPV E2 controls the promoters of these SR 543 
proteins via its trans-activation domain. SRSF3 levels showed the greatest change with a 544 
71% decrease detected in cells expressing the mutant E2 compared to wild type E2. The 545 
reported increased levels of E2 in the mid to upper layers of HPV-infected epithelia [5,6] fits 546 
well with the increase in SRSF1-3 expression in differentiating compared to undifferentiated 547 
W12E cells [24], NIKS16 and CIN612-9E cells (this study). It will be of interest to determine if 548 
other high risk and low risk HPV types control SRSFs during the infectious life cycle. Our 549 
data imply that E2 control of SRSF1-3 is likely at the level of transcription initiation. However, 550 
because E2 has been shown to possess some properties of SR proteins [44-46] we cannot 551 
discount a direct E2-mediated regulation of HPV mRNA processing or indeed E2 control of 552 
alternatively spliced isoforms of SR protein mRNAs that are more stimulatory of L1 splicing. 553 
Also, although E2 is a regulator of SRSFs we cannot rule out the possibility that other HPV 554 
proteins could be involved in controlling SRSF expression. For example, E6 and E7 may 555 
activate cellular transcription factors and control SRSF levels indirectly in differentiated 556 
keratinocytes [47,48]. 557 
 558 
Our data suggest that a specific subset of SR proteins (SRSFs1-3) is regulated by E2, 559 
indicating that these proteins may have important functions during the HPV replicative life 560 
cycle. Reasoning that increased SR protein expression in differentiated keratinocytes might 561 
impact late events in the viral life cycle we compared the effect of siRNA depletion of each of 562 
the E2-regulated SRSFs1-3 with SRSF5 and 7 (the latter two of which are not controlled by 563 
E2 in the NIKS16 model) on capsid protein expression. Depletion of SR proteins 2, 5 and 7 564 
had no significant effect on L1 protein expression. Depletion of SRSF1 caused a modest 565 
reduction in L1 protein expression in NIKS16 and W12 cells as predicted by a previous study 566 
[20]. However, SRSF3 depletion caused a major reduction in L1 protein expression in the 567 
differentiated NIKS16 cells. SRSF3 control of L1 expression was confirmed in a second 568 
HPV16 life cycle model using W12E cells. Conversely, overexpression of SRSF3 in 569 
undifferentiated NIKS16 cells resulted in some induction of L1 protein expression. We were 570 
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unable to repeat the experiment in the W12 cell model due to problems inhibiting 571 
differentiation in these cells during the course of the overexpression experiment. Although 572 
further work is required to determine whether the effect of SRSF3 on L1 induction in 573 
undifferentiated epithelial cells is at the level of mRNA processing, our data indicate that 574 
SRSF3 is a key regulator of viral capsid protein expression. 575 
 576 
Although we did not carry out SR protein depletion experiments in CIN612-9E cells, we 577 
observed a significant decrease in capsid protein production in human keratinocytes 578 
maintaining E2:I73L mutant genomes, with a concomitant 50% reduction in SRSF3 579 
expression, compared to cells containing wild type HPV31 genomes. This does not prove 580 
that SRSF proteins control L1 protein production in HPV31-positive keratinocytes but it is 581 
correlative with the observations in the HPV16-positive lines. The approximately 4-fold level 582 
of L1 protein depletion we observed (Figure 2D) agrees with the 80% reduction observed 583 
previously in L1 mRNA production in foreskin keratinocytes expressing the HPV31 E2:I73L 584 
mutant genome [30]. The greater effect of the E2 inactivating point mutation on L1 protein 585 
expression compared to SRSF3 depletion could be due to incomplete knock down of SRSF3 586 
in our experiments. However, it may be due to other effects of E2 on HPV or cellular gene 587 
expression. E2 appears to be required for induction of HPV late mRNA expression by 588 
inhibiting the viral early polyadenylation signal through interaction with CPSF30 [11]. While in 589 
our study an HPV31 E2 transactivation domain point mutant was all that was required to 590 
reduce virus capsid protein expression, in the study by Johannson et al. both the E2 591 
transactivation domain and the hinge region were required for control of L1 and L2 mRNA 592 
levels [11]. This suggests that there at least two E2-regulated mechanisms for controlling the 593 
viral late gene expression and these are not mutually exclusive. Apart from these important 594 
mechanisms, E2 can bind other RNA processing factors, including SR proteins SRSFs 1, 2, 595 
and 7 [49] and could modulate their splicing activities as well as or instead of controlling 596 
transcription of SRSF genes. Moreover, E2 possesses SR protein-like properties itself as it 597 
can bind RNA and affect splicing in vitro [44, 45]. Importantly, a recent study revealed that in 598 
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U2OS cells E2 can control human gene expression by inducing alternative splice isoforms of 599 
mRNAs that encode proteins involved in cancer formation and cell motility [46]. Therefore, it 600 
is possible that E2 could control late mRNA expression directly. A complex combination of 601 
different E2-regulated mechanisms may be essential in differentiation stage-specific control 602 
of HPV gene expression. 603 
 604 
Several previous studies have reported the effects of SR proteins on HPV gene expression. 605 
These reports have delineated ESEs and ESSs and their interacting proteins on viral RNAs. 606 
SRSF1 binds a downstream ESE in the E4 open reading frame to control the viral splice 607 
acceptor site 3258 [20]. SRSF2 controls HPV16 oncoprotein expression by regulating mRNA 608 
stability [23]. SRSF3 also controls HPV16 oncoprotein expression [19] but to a lesser extent 609 
than SRSF2 [23]. SRSF9 can activate the E4 splice donor 3632 while inhibiting splice 610 
acceptor 3358 at the 5’ end of the E4 open reading frame [21]. Of interest, another splicing 611 
control element in the E4 coding region [50] binds SRSF3 [19]. Knocking down SRSF3 in 612 
U2OS osteosarcoma cells increased levels of both L1 and L2 mRNAs while mutating the 613 
SRSF3 binding site increased L1 mRNA production almost two-fold [19]. In contrast to this 614 
study, we found that SRSF3 depletion in undifferentiated epithelial cells did not induce L1 615 
protein expression (Figure 3E). Moreover, our data indicate that SRSF3 is required for the 616 
L1-encoding E4^L1 mRNA and L1 protein expression in differentiating keratinocytes. 617 
Although some of the effects we have observed are rather modest, the differences in our 618 
data compared to the previous studies can be attributed to our use of differentiating, HPV-619 
infected non-tumour epithelial cells (three different model systems) that better mimic the 620 
natural HPV life cycle. Further, wild type HPV genomes are present in NIKS16 and W12E 621 
and CIN612-9E cells. In contrast, in the previous studies, subgenomic constructs with 622 
deletions in important cis-acting elements (e.g. the late negative regulatory region [51]) 623 
controlling gene expression were used [20,21,50]. In our HPV-infected lines, viral 624 
transcription is driven from the natural viral promoters [10,38] which are relatively weakly 625 
active. Expression of HPV late mRNAs from the subgenomic constructs is under control of 626 
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the strong CMV promoter. Of importance, RNA polymerase II elongation rate, determined by 627 
promoter strength, is a major determinant of the use of weak over strong splice sites 628 
regardless of ESE/ESS activity [52,53]. Finally, the exact levels of SR proteins in cells are 629 
known to be vital to their function in splicing [54] meaning the effects on HPV late gene 630 
expression of the SRSF levels found in undifferentiated tumour cells may be different to their 631 
effects in differentiated keratinocytes. 632 
 633 
However, it is important to consider that because we have analysed HPV gene expression 634 
together with keratinocyte differentiation upon SRSF knockdown, some of the effects we 635 
observed could be an indirect result of SRSF-mediate control of other cellular factors or of 636 
epithelial differentiation itself. For example, in Figure 6A we observed an increase in 637 
expression of the epithelial differentiation marker involucrin upon SRSF3 depletion implying 638 
that SRSF3 may repress involucrin expression upon epithelial differentiation. Further work 639 
will be required to determine whether SRSF3 is controlling HPV late gene expression directly 640 
or whether it does so through other cellular pathways. 641 
 642 
Immunohistochemical staining of HPV16-infected low grade cervical lesions has revealed a 643 
distinct pattern of SRSF3 expression [24](this study). SRSF3 is expressed in the majority of 644 
basal epithelial cells. Although fewer cells in the upper epithelial layers express SRSF3 645 
those that do express the protein contain very densely stained nuclei (Figure 3F). We 646 
propose that these cells are HPV-infected and supporting late events in the viral replication 647 
cycle including E2-mediated control of SRSF3 expression. In preparation for capsid protein 648 
production, viral late mRNAs may be produced in epithelial cells below the granular layer [8] 649 
colocating with high levels of E2 and SRSF3. SRSF3 appears to be required for expression 650 
of the E4^L1 late mRNA that encodes the L1 capsid protein. Conversely, SRSF1 and 651 
SRSF3 negatively regulate production of the L2L1 read through RNA that likely encodes L2. 652 
This could be one regulatory mechanism that ensures high levels of L1 and low levels of L2 653 
protein production to provide the correct ratio of L1 to L2 protein for capsid formation. 654 
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SRSF3 can cross-regulate SRSF2, SRSF5 and SRSF7 and has been proposed as a master 655 
regulator of RNA splicing [41]. The cooperative activity of SR proteins imposes positive and 656 
negative combinatorial control on splicing [54]. Therefore, in future it will be important to 657 
examine the effect of siRNA depletion of combinations of E2-controlled SR proteins on the 658 
HPV gene expression programme.  659 
 660 
In conclusion, if HPV-regulated SR proteins are key to completion of the viral replication 661 
cycle they may represent a useful target for antiviral therapy. Small molecule inhibitors of SR 662 
protein kinases that modulate the functions of SR proteins are available. As they have been 663 
shown to be effective in inhibiting replication of HIV, hepatitis C virus and Sindbis virus [14] 664 
they have potential to be effective against HPV replication. However, it will also be important 665 
also to understand any potential effects of these therapies on the switch from the viral 666 
replicative cycle to persistent or latent infection that underlies tumour progression. 667 
Nevertheless, such targets may prove effective for future therapeutic study. 668 
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FIGURE LEGENDS 685 
 686 
Figure 1 HPV16 E2 trans-activates the promoters of SRSFs 1-3. (A) Western blot 687 
analysis of levels of E2 protein in two clones of U2OS cells (U2OSA4, U2OSB1) stably 688 
transfected with an HPV16 E2 expression vector [29]. U2OSv, cells transfected with empty 689 
vector. GAPDH is shown as a control for protein loading levels. (B) Luciferase transcription 690 
assays reveal E2-transactivation of the SRSF1-3 promoters. Graph of luciferase activity in 691 
U2OSv (dark grey bars), U2OSA4 (light grey bars) and U2OSB1 (mid grey bars) cells 692 
transiently transfected with luciferase expression vectors under control of the promoters 693 
shown on the X-axis or the promoterless vector, pGL3, as a negative control. The mean and 694 
standard deviation from the mean of three separate experiments is shown. Asterisks show 695 
statistically significant change (p value) using a student’s T-test (two-tailed). * p<0.05. *** 696 
p<0.001. 697 
Figure 2. The transactivation domain of HPV31 E2 is required for control of SRSF1-3 698 
and production of L1 protein. (A) SRSF levels are increased in differentiated HPV31-699 
infected CIN612-9E cells. Semi-quantitative western blot analysis of levels of SR proteins in 700 
undifferentiated (U) and differentiated (D) CIN612-9E cells. 5, 10 or 20μg protein extracts 701 
were loaded as indicated above the blots. SRSF1, 3, and 7 were detected with specific 702 
monoclonal antibodies as indicated on the right hand side of the blots. SRSF1, 2, 4, 5 and 6 703 
were detected with Mab104 that detects phosphoepitopes of all the classical SR proteins 704 
except SRSF9. Involucrin was detected as a control for differentiated epithelial cells. 705 
Involucrin is detected in the undifferentiated cells due to around 20% of these having 706 
undergone differentiation. GAPDH was detected as a protein loading control. A single gel 707 
was blotted and probed with antibodies against SRSF1 and involucrin. The same samples 708 
were electrophoresed on identical gels for probing with GAPDH and SRSF7 or with Mab104 709 
and SRSF3. This experiment was repeated three times with very similar results from each 710 
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western blot. (B) Keratinocytes containing a transactivation-negative E2 point mutant HPV31 711 
genome have reduced levels of SRSF1-3. Western blot analysis of SRSF1-3 levels in 712 
normal human foreskin keratinocytes (NFKs) stably transfected with wild type (E2wt) or point 713 
mutant E2:I73L HPV31 genomes (E2:IL73). SRSF7 was detected as a control for an SR 714 
protein whose levels are not changed upon epithelial differentiation or significantly trans-715 
activated by HPV16E2. Levels of L1 protein in the two lines are also shown. The experiment 716 
was carried out three times using two different clones of each E2-expressing keratinocyte 717 
line. Very similar results were obtained in each experiment. (C) Western blot analysis of 718 
levels of E2 protein and differentiation status of NFKs stably transfected with wild type 719 
(E2wt) or point mutant E2:I73L HPV31 genomes (E2:IL73). As a marker of differentiation, 720 
levels of involucrin are shown in undifferentiated (U) and differentiated (D) CIN6129E 721 
keratinocytes for comparison. The experiment was carried out twice using two different 722 
clones of each E2-expressing keratinocyte line. Very similar results were obtained in each 723 
experiment. (D) Quantification of levels of the SR proteins shown in (B). The graph shows 724 
the mean and standard deviation from the mean of three separate experiments. Values were 725 
calculated relative to GAPDH levels. Very similar data were obtained with two different 726 
clones of each keratinocyte line. (E) Western blot quantification of levels of L1 protein in 727 
differentiated NFKs stably maintaining wild type HPV31 and in NFKs stably maintaining point 728 
mutant E2:I73L HPV31 genomes. The graph shows the mean and standard deviation from 729 
the mean from three separate experiments. Values were calculated relative to GAPDH 730 
levels. P-values were calculated using a student’s T-test. 731 
Figure 3 SRSF3 levels increase upon differentiation of HPV16-infected cells (A) 732 
SRSF1-3 levels do not alter upon differentiation of HPV-negative NIKS cells. Semi-733 
quantitative western blot analysis of levels of SR proteins in undifferentiated (U) and 734 
differentiated (D) NIKS cells. 5, 10 or 20μg protein extracts were loaded as indicated above 735 
the blots. SRSF3 was detected with a specific monoclonal antibody 7B4. SRSF1, 2, 4, 5 and 736 
6 were detected with Mab104. SRSF7 was not tested in this experiment because its levels 737 
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did not change upon HPV infection [24]. Involucrin was detected as a control for 738 
differentiation of epithelial cells. GAPDH was detected as a protein loading control. 739 
(B)SRSF1-3 levels are increased in differentiated NIKS16 cells. Semi-quantitative western 740 
blot analysis of levels of SR proteins in undifferentiated (U) and differentiated (D) NIKS16 741 
cells. 5, 10 or 20μg protein extracts were loaded as indicated above the blots. SRSF3 and 7 742 
were detected with specific monoclonal antibodies. SRSF1, 2, 4, 5 and 6 were detected with 743 
Mab104. Involucrin was detected as a control for differentiated epithelial cells. GAPDH was 744 
detected as a protein loading control. The experiments in (A) and (B) were carried out at 745 
least three times with very similar results obtained each time. (C) Quantification of SRSF3 746 
levels in undifferentiated (U) and differentiated (D) HPV-negative NIKS cells. The graph 747 
shows the mean and standard deviation from the mean from three separate experiments. 748 
Values were calculated relative to GAPDH levels. (D) Quantification of SRSF3 levels in 749 
undifferentiated (U) and differentiated (D) NIKS16 cells. The graph shows the mean and 750 
standard deviation from the mean from five separate experiments. Values were calculated 751 
relative to GAPDH levels. (E) Immunohistochemical staining of a representative normal 752 
cervical epithelium (10 normal lesions were stained) with an antibody against SRSF3. Note 753 
the strongly stained nuclei are present mainly in the lower epithelial layers. (F) 754 
Immunohistochemical staining of a representative low grade cervical lesion (10 low grade 755 
lesions were stained) with an antibody against SRSF3. Note the strongly stained nuclei in 756 
the mid to upper epithelial layers. The picture in ( E) is taken at lower magnification than that 757 
in (F) to show that the staining pattern is consistent over a wide area of tissue.  758 
Figure 4. SRSF3 is required for L1 protein expression. (A) Western blot analysis of SR 759 
protein depletion for the experiment shown in (E). SRSF1, 3 and 7 were detected with 760 
specific antibodies. SRSF1, 2 and 5 were detected with Mab104. The panel showing SRSF2 761 
depletion was probed with Mab104. Only the area of the blot showing SRSF2 and SRSF1 762 
bands is shown. SRSF2 is the upper band.  U, undifferentiated, D, differentiated NIKS16 763 
cells. Cntrl, cells transfected with a control siRNA. (B) SRSF3 depletion results in reduced L1 764 
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protein levels. Western blot analysis of L1 protein in, differentiated keratinocytes (D) with the 765 
various SR proteins depleted. (U), undifferentiated NIKS16 cell extracts were analysed as a 766 
negative control for L1 protein expression. Cntrl, cells transfected with a control siRNA. 767 
Involucrin was detected as a control for differentiated epithelial cells. GAPDH was detected 768 
as a protein loading control. (C) Quantification of levels of L1 protein in NIK16 keratinocytes 769 
transfected with a control siRNA (cntrl) or siRNAs against each of the SR proteins shown on 770 
the X-axis. U, undifferentiated keratinocytes D, differentiated keratinocytes. The graph 771 
shows the mean and standard deviation from the mean from three separate experiments. 772 
Values were calculated relative to GAPDH levels. P-value was calculated using a student’s 773 
T-test. 774 
 775 
Figure 5 SRSF3 controls L1 protein levels in W12E cells. (A) Western blot analysis of 776 
SRSF1 and 3 protein depletion by siRNA in U, undifferentiated and D, differentiated W12E 777 
cells. Much higher levels of SRSF1 and SRSF3 were detected in differentiated W12E cells 778 
as expected [24]. L1 protein was not detected in U, undifferentiated W12E cells even with 779 
SRSF1 or SRSF3 depletion. L1 protein was detected in D, differentiating W12E cells but 780 
levels were reduced in the cells treated with siRNA against SRSF3. Cntrl, cells transfected 781 
with a control siRNA. Involucrin was detected as a control for differentiated epithelial cells. 782 
GAPDH was detected as a protein loading controlThis experiment was carried out five times 783 
and very similar data were obtained each time. (B) Western blot quantification of levels of L1 784 
protein in differentiated W12E keratinocytes transfected with a control siRNA (cntrl) or 785 
siRNAs against SRSF1 or SRSF3. The graph shows the mean and standard deviation from 786 
the mean from three separate experiments. Values were calculated relative to GAPDH 787 
levels. P-value was calculated using a student’s T-test. (C) Undifferentiated NIKS16 cells 788 
were transfected with vector control (Cntrl: lane 2) or a plasmid encoding the SRSF3 protein 789 
(SRSF3 transfect: lane 3). Differentiated NIK16 cell extract (DNIKS16, lane 1) was probed 790 
as a positive control for L1 expression. GAPDH was used as a loading control. Involucrin 791 
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was detected as a marker of epithelial differentiation. The level of involucrin was so high in 792 
the differentiated compared to the undifferentiated NIK16 cell extracts that the blot was 793 
bleached out in lane 1. The experiment was repeated twice and very similar data were 794 
obtained each time. 795 
 796 
Figure 6 SRSF3 controls levels of the E4^L1 mRNA. (A) Schematic diagram of the 797 
HPV16 genome. Open reading frames are represented with light grey boxes with the gene 798 
names beneath. Promoters are indicated with arrowheads. Polyadenylation sites are 799 
indicated with downward arrows (Poly(A)E/L). The major late mRNA splicing events with the 800 
open reading frames (dark grey boxes) and introns (dark grey lines) are indicated below the 801 
genome map. Each mRNA is shown truncated at the 5’ end to indicated the presence of 802 
several possible initiation sites for transcription of these mRNAs [10]. The open reading 803 
frames in each mRNA are indicated to the right hand side. (B) Western blot analysis of levels 804 
of SRSF1 and SRSF3 in NIKS16 cells following siRNA knock down. siSRSF1, siRNA 805 
against SRSF1. siSRSF3, siRNA against SRSF3. siCntrl, control siRNA. GAPDH was 806 
detected as a protein loading control. (C) RT-PCR detection of HPV late mRNAs type B 807 
(upper gel) or type C (lower gel) in cDNA synthesized from RNA isolated from the same cell 808 
populations analysed in (B). Cntrl, control siRNA. SRSF1, siRNA against SRSF1. SRSF3, 809 
siRNA against SRSF3. RT, reverse transcriptase. M, 1Kb DNA marker ladder. GAPDH was 810 
amplified as an internal control for RNA concentrations. (D) Relative levels of E4^L1 spliced 811 
mRNA B compared to GAPDH mRNA determined by qPCR. The mean and standard 812 
deviation from the mean are shown from three separate experiments. (E) Relative levels of 813 
unspliced L2L1 mRNAs C compared to GAPDH mRNA determined by qPCR. The mean and 814 
standard deviation from the mean are shown from three separate experiments. P-values 815 
were calculated using a student’s T-test. 816 
  817 
34 
 
REFERENCES 818 
 819 
 1.  zur Hausen H. 2009. Papillomaviruses in the causation of human cancers - a brief 820 
historical account. Virology 384: 260-265. 821 
 2.  Graham SV. 2010. Human papillomavirus: gene expression, regulation and 822 
prospects for novel diagnostic methods and antiviral therapies. Future Microbiol 5: 823 
1493-1505. 824 
 3.  Groves IJ, Coleman N. 2015. Pathogenesis of human papillomavirus-associated 825 
mucosal disease. J Pathol 235: 527-538. 826 
 4.  Doorbar J. 2005. The papillomavirus life cycle. J Clin Virol 32S: S7-S15. 827 
 5.  Xue Y, Bellanger S, Zhang W, Lim D, Low J, Lunny D, Thierry F. 2010. HPV16 E2 828 
is an immediate early marker of viral infection, preceding E7 expression in precursor 829 
structures of cervical carcinoma. Cancer Res 70: 5316-5325. 830 
 6.  Coupe VM, Gonzalez-Barreiro L, Gutierrez-Berzal J, Melian-Boveda AL, Lopez-831 
Rodriguez O, Alba-Dominguez J, Alba-Losada J. 2012. Transcriptional analysis of 832 
human papillomavirus type 16 in histological sections of cervical dysplasia by in situ 833 
hybridisation. J Clin Pathol 65: 164-170. 834 
 7.  McBride AA. 2013. The papillomavirus E2 proteins. Virology 445: 57-79. 835 
 8.  Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. 1992. 836 
Human papillomavirus type 16 and 18 gene expression in cervical neoplasia. Human 837 
Pathol 23: 117-128. 838 
 9.  Zhou J, Lui.W.J., Peng SW, Sun XY, Frazer IH. 1999. Papillomavirus capsid protein 839 
expression levels depends on the match between codon usage and tRNA availability. 840 
J Virol 73: 4972-4982. 841 
35 
 
 10.  Milligan SG, Veerapraditsin T, Ahamat B, Mole S, Graham SV. 2007. Analysis of 842 
novel human papillomavirus type 16 late mRNAs in differentiated W12 cervical 843 
epithelial cells. Virology 360: 172-181. 844 
 11.  Johannson C, Somberg M, Li X, Winquist EB, Fay J, Ryan F, Pim D, Banks L., 845 
Schwartz S. 2012. HPV-16 E2 contributes to induction of HPV-16 late gene 846 
expression by inhibiting early polyadenylation. EMBO J 31: 3212-3227. 847 
 12.  Johannson C, Schwartz S. 2013. Regulation of human papillomavirus gene 848 
expresion by splicing and polyadenylation. Nat Rev Microbiol 11: 239-251. 849 
 13.  Singh RK, Cooper TA. 2012. Pre-mRNA splicing in disease and therapeutics. 850 
Trends Mol Med 18: 472-482. 851 
 14.  Hernandez-Lopez HR, Graham SV. 2012. Alternative splicing in tumour viruses: a 852 
therapeutic target? Biochem J 445: 145-156. 853 
 15.  Busch A, Hertel KJ. 2012. Evolution of SR proteins and hnRNP splicing regulatory 854 
factors. Wiley Interdiscip Rev RNA 3: 1-12. 855 
 16.  Roca X, Krainer AR, Eperon IC. 2013. Pick one, but be quick:5' splice sites and the 856 
problem of too many choices. Genes Dev 27: 129-144. 857 
 17.  Long JC, Caceres JF. 2009 The SR protein family of splicing factors: master 858 
regulators of gene expression. Biochem J 417: 15-27. 859 
 18.  Kajitani N, Schwartz S. 2015. RNA binding proteins that control human 860 
papillomavirus gene expression. Biomolecules 5: 758-774. 861 
 19.  Jia R, Liu X, Tao M, Kruhlak M, Guo M, Meyers C, Baker CC, Zheng ZM. 2009. 862 
Control of the papillomavirus early-to-late switch by differentially expressed SRp20. J 863 
Virol 83: 167-180. 864 
36 
 
 20.  Somberg M, Schwartz S. 2010. Multiple ASF/SF2 sites in the human papillomavirus 865 
type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-866 
splice Site on the HPV-16 genome. J. Virol. 84: 8219-8230. 867 
 21.  Somberg M, Li X, Johannson C, Orru B, Chang R, Rush M, Fay J, Ryan F, 868 
Schwartz S. 2011. Serine/arginine-rich protein 30c activates human papillomavirus 869 
type 16 L1 mRNA expression via a bimodal mechanism. J Gen Virol 92: 2411-2421. 870 
 22.  Li X, Johansson C, Cardoso Palacios C, Mossberg A, Dhanjal S, Bergvall M, 871 
Schwartz S. 2013. Eight nucleotide substitutions inhibit splicing to HPV-16 3'-splice 872 
site SA3358 and reduce the efficiency by which HPV-16 increases the life span of 873 
primary human keratinocytes. PLoS One 8: e72776. 874 
 23.  McFarlane M, MacDonald AI, Stevenson A, Graham SV. 2015. Human 875 
papillomavirus 16 oncoprotein expression is controlled by the cellular splicing factor 876 
SRSF2 (SC35). J Virol 89: 5276-5287. 877 
 24.  Mole S, McFarlane M, Chuen-Im T, Milligan SG, Millan D, Graham SV. 2009. RNA 878 
splicing factors regulated by HPV16 during cervical tumour progression. J Pathol 219: 879 
383-391. 880 
 25.  Mole S, Milligan SG, Graham SV. 2009. Human papillomavirus type 16 E2 protein 881 
transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF. J 882 
Virol 83: 357-367. 883 
 26.  Jeon S, Allen-Hoffman BL, Lambert PF. 1995. Integration of human papillomavirus 884 
type 16 into the human genome correlates with a selective growth advantage of cells. 885 
J Virol 69: 2989-2997. 886 
 27.  Weschler EI, Wang Q, Roberts I, Pagliarulo E, Jackson D, Untersperger C, 887 
Coleman N, Griffin H, Doorbar J. 2012. Reconstruction of human papillomavirus 888 
37 
 
type 16-mediated early-stage neoplasia implicated E6/E7 deeregulation and the loss 889 
of contact inhibition in neoplastic progression. J Virol 86: 6358-6364. 890 
 28.  Hummel M, Hudson JB, Laimins LA. 1992. Differentiation-induced and constitutive 891 
transcription of human papillomavirus type 31b in cell lines containing viral episomes. 892 
J Virol 66: 6070-6080. 893 
 29.  Taylor ER, Boner W, Dornan ES, Corr EM, Morgan IM. 2003. UVB irradiation 894 
reduces the half life and transactivation poteintial of the human papillomavirus 16 E2 895 
proteins. Oncogene 22: 4469-4477. 896 
 30.  Stubenrauch F, Colbert AME, Laimins LA. 1998. Transactivation by the E2 protein 897 
of oncogenic human papillomavirus type 31 is not essential for early and late viral 898 
functions. J Virol 72: 8115-8123. 899 
 31.  McPhillips MG, Veerapraditsin T, Cumming SA, Karali D, Milligan SG, Boner W, 900 
Morgan IM, Graham SV. 2004. SF2/ASF binds the human papillomavirus type 16 901 
late RNA control element and is regulated during epithelial differentiation. J Virol 78: 902 
10598-10605. 903 
 32.  Fay J, Kelehan P, Lambkin H, Schwartz S. 2009. Increased expression of cellular 904 
RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J Med Virol 81: 905 
897-907. 906 
 33.  Lee D, Kim H-Z, Jeong KW, Shim YS, Horikawa I, Barrett JC, Choe J. 2002 907 
Human papillomavirus E2 down-regulates the human telomerase reverse 908 
transcriptase promoter. J Biol Chem 277: 27748-27756. 909 
 34.  Frolkis M, Fischer MB, Wang Z, Lebkowski JS, Chiu C-P, Majumdar AS. 2003. 910 
Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-911 
cell response against different types of tumors. Cancer Gene Ther 10: 239-249. 912 
38 
 
 35.  Stanley MA, Browne HM, Appelby M, Minson AC. 1989. Properties of a non-913 
tumourigenic human cervical keratinocyte cell line. Int J Cancer 43: 672-676. 914 
 36.  Chuen-Im T, Zhang J, Milligan SG, McPhillips MG, Graham SV. 2008. The 915 
alternative splicing factor hnRNP A1 is up-regulated during virus-infected epithelial 916 
cell differentiation and binds the human papillomavirus type 16 late regulatory 917 
element. Virus Res 131: 189-198. 918 
 37.  Hummel M, Lim HB, Laimins LA. 1995 Human papillomavirus type 31b late gene 919 
expression is regulated through protein kinase C-mediated changes in RNA 920 
processing. J Virol 69: 3381-3388. 921 
 38.  Ozbun MA, Meyers C. 1997. Characterisation of late gene transcripts expressed 922 
during vegetative replication of human papillomavirus type 31b. J Virol 71: 5161-923 
5172. 924 
 39.  Gauson EJ, Donaldson MM, Dornan ES, Wang X, Bristol M, Bodily JM, Morgan 925 
IM. 2015. Evidence supporting a role for TopBP1 and Brd4 in the initiation but not 926 
continuation of human papillomavirus 16 E1/E2-mediated DNA replication. J Virol 89: 927 
4980-4990. 928 
 40.  Corbo C, Orru S, Salvatore F. 2013. SRp20: An overview of its role in human 929 
         disease. Biochem Biophys Res Comm 436: 1-5. 930 
 41.  Anko M-L, Muller-McNicoll M, Brandi H, Curk T, Gorup C, Henry I, Ule J, 931 
Neugebauer KM. 2012. The RNA-binding landscapes of two SR proteins reveal 932 
unique functions and binding to diverse RNA classes. Genome Biol 13: R17. 933 
 42.  Wang X, Meyers C, Wang H, Chow LT, Zheng ZM. 2011. Construction of a full 934 
transcription map of human papillomavirus type 18 during productive viral infection. J 935 
Virol 85: 8080-8092. 936 
39 
 
 43.  Schmitt M, Dalstein V, Waterboer T, Clavel.C., Gissman L, Pawlita M. 2010. 937 
Diagnosing cervical cancer and high grade precursors by HPV16 transcription 938 
patterns. Cancer Res 70: 249-256. 939 
44.    Lai M-C, Teh BH, Tarn W-Y. 1999 A human papillomavirus E2 transcriptional 940 
activator. J Biol Chem 274: 11832-11841. 941 
45.     Bodaghi S, Jia R, Zheng Z. 2009. Human papillomvirus type 16 E2 and E6 are 942 
RNA-binding proteins and inhibit in vitro splicing of pre-mRNA with suboptimal splice 943 
sites. Virology 386: 32-43. 944 
46.    Gauson EJ, Windle B, Donaldson MM, Caffarel MM, Dornan ES, Coleman N, 945 
Henderson SC, Wang X, Morgan IM. 2014. Regulation of human genome 946 
expression and RNA splicing by human papillomavirus E2 protein. Virology 468-470: 947 
10-18. 948 
 47.  Roman A, Munger K. 2013. The papillomavirus E7 proteins. Virology 445: 138-168. 949 
 48.  Vande Pol SB, Klingelhutz AJ. 2013. Papillomavirus E6 proteins. Virology 445: 115-950 
137. 951 
 49.  Muller M, Demert C. 2012. The HPV E2-host protein-protein interactions: a complex 952 
hijacking of the cellular network. Open Virol J 6: 173-189. 953 
 50.  Rush M, Zhao X, Schwartz S. 2005)=. A splicing enhancer in the E4 coding region 954 
of human papillomavirus type 16 is required for early mRNA splicing and 955 
polyadenylation as well as inhibition of premature late gene expression. J Virol 79: 956 
12002-12015. 957 
 51.  Graham SV. 2008. Papillomavirus 3'UTR regulatory elements. Frontiers Biosci. 13: 958 
5646-5663. 959 
40 
 
 52.  Proudfoot N. 2000. Connecting transcription to messenger RNA processing. Trends 960 
Biochem Sci 25: 290-293. 961 
 53.  Moreno NN, Giono LE, Cambindo Botto AE, Munoz MJ, Kornblihtt AR. 2015. 962 
Chromatin, DNA structure and alternative splicing. FEBS Lett In press. 963 
 54.  Bradley T, Cook ME, Blanchette M. 2015. SR proteins control a complex network of 964 
RNA-processing events. RNA 21: 75-92. 965 
 966 
 967 
 968 
Figure 1 Klymenko et al.
*
*
***
*
0
200000
400000
600000
800000
1000000
1200000
pGL-3 
empty
hTERT SRSF1 SRSF2 SRSF3 SRSF7
Re
la
tiv
e l
uc
ife
ra
se
 a
ct
ivi
ty
SRSF promoter activity in the presence
of HPV16 E2 transcription factor 
U2OSv
U2OS A4
U2OS B1
A
B
E2
GAPDH
U
2O
Sv
U
2O
SA
4
U
2O
SB
1
kDa
42
38
***
*
Figure 1 HPV16 E2 trans-activates the promoters of SRSFs 1-3. (A) Western blot analysis of levels of E2
protein in two clones of U2OS cells (U2OSA4, U2OSB1) stably transfected with an HPV16 E2 expression
vector [29]. U2OSv, cells transfected with empty vector. GAPDH is shown as a control for protein loading
levels. (B) Luciferase transcription assays reveal E2-transactivation of the SRSF1-3 promoters. Graph of
luciferase activity in U2OSv (dark grey bars), U2OSA4 (light grey bars) and U2OSB1 (mid grey bars) cells
transiently transfected with luciferase expression vectors under control of the promoters shown on the X-axis
or the promoterless vector, pGL3, as a negative control. The mean and standard deviation from the mean
of three separate experiments is shown. Asterisks show statistically significant change (p value) using a
student’s T-test (two-tailed). * p<0.05. *** p<0.001.
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Figure 2. The transactivation domain of HPV31 E2 is required for control of SRSF1-3 and production of L1 protein.
(A) SRSF levels are increased in differentiated HPV31-infected CIN612-9E cells. Semi-quantitative western blot
analysis of levels of SR proteins in undifferentiated (U) and differentiated (D) CIN612-9E cells. 5, 10 or 20μg protein
extracts were loaded as indicated above the blots. SRSF1, 3, and 7 were detected with specific monoclonal
antibodies as indicated on the right hand side of the blots. SRSF1, 2, 4, 5 and 6 were detected with Mab104 that
detects phosphoepitopes of all the classical SR proteins except SRSF9. Involucrin was detected as a control for
differentiated epithelial cells. Involucrin is detected in the undifferentiated cells due to around 20% of these having
undergone differentiation. GAPDH was detected as a protein loading control. A single gel was blotted and probed
with antibodies against SRSF1 and involucrin. The same samples were electrophoresed on identical gels for probing
with GAPDH and SRSF7 or with Mab104 and SRSF3. This experiment was repeated three times with very similar
results from each western blot. (B) Keratinocytes containing a transactivation-negative E2 point mutant HPV31
genome have reduced levels of SRSF1-3. Western blot analysis of SRSF1-3 levels in normal human foreskin
keratinocytes (NFKs) stably transfected with wild type (E2wt) or point mutant E2:I73L HPV31 genomes (E2IL73).
SRSF7 was detected as a control for an SR protein whose levels are not changed upon epithelial differentiation
or significantly trans-activated by HPV16E2. Levels of L1 protein in the two lines are also shown. The experiment
was carried out three times using two different clones of each E2-expressing keratinocyte line. Very similar results
were obtained in each experiment. (C) Western blot analysis of evels of E2 protein and differentiation status of
NFKs stably transfected with wild type (E2wt) or point mutant E2:I73L HPV31 genomes (E2IL73). As a marker of
differentiation, levels of involucrin are shown in undifferentiated (U) and differentiated (D) CIN6129E keratinocytes
for comparison. The experiment was carried out twice using two different clones of each E2-expressing keratinocyte
line. Very similar results were obtained in each experiment. (D) Quantification of levels of the SR proteins shown in
(B). The graph shows the mean and standard deviation from the mean of three separate experiments. Values were
calculated relative to GAPDH levels. Very similar data were obtained with two different clones of each keratinocyte
line. (E) Western blot quantification of levels of L1 protein in differentiated NFKs stably maintaining wild type HPV31
and in NFKs stably maintaining point mutant E2:I73L HPV31 genomes. The graph shows the mean and standard
deviation from the mean from three separate experiments. Values were calculated relative to GAPDH levels. P-values
were calculated using a student’s T-test.
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Figure 3 SRSF3 levels increase upon differentiation of HPV16-infected cells (A) SRSF1-3 levels do not alter upon
differentiation of HPV-negative NIKS cells. Semi-quantitative western blot analysis of levels of SR proteins in
undifferentiated (U) and differentiated (D) NIKS cells. 5, 10 or 20μg protein extracts were loaded as indicated
above the blots. SRSF3 was detected with a specific monoclonal antibody B7H4. SRSF1, 2, 4, 5 and 6 were
detected with Mab104. SRSF7 was not tested in this experiment because its levels did not change upon HPV
infection [24]. Involucrin was detected as a control for differentiated epithelial cells. GAPDH was detected as a
protein loading control. (B) SRSF1-3 levels are increased in differentiated NIKS16 cells. Semi-quantitative western
blot analysis of levels of SR proteins in undifferentiated (U) and differentiated (D) NIKS16 cells. 5, 10 or 20μg
protein extracts were loaded as indicated above the blots. SRSF3 and 7 were detected with specific monoclonal
antibodies. SRSF1, 2, 4, 5 and 6 were detected with Mab104. Involucrin was detected as a control for differentiated
epithelial cells. GAPDH was detected as a protein loading control. The experiments in (A) and (B) were carried out
at least three times with very similar results obtained each time. (CB) Quantification of SRSF3 levels in undifferentiated
(U) and differentiated (D) HPV-negative NIKS cells. The graph shows the mean and standard deviation from the
mean from three separate experiments. Values were calculated relative to GAPDH levels. (D) Quantification of
SRSF3 levels in undifferentiated (U) and differentiated (D) NIKS16 cells. The graph shows the mean and standard
deviation from the mean from five separate experiments. Values were calculated relative to GAPDH levels. (E)
Immunohistochemical staining of a representative normal cervical epithelium (10 normal lesions were stained)
with an antibody against SRSF3. Note the strongly stained nuclei are present mainly in the lower epithelial layers.
(F) Immunohistochemical staining of a representative low grade cervical lesion (10 low grade lesions were stained)
with an antibody against SRSF3. Note the strongly stained nuclei in the mid to upper epithelial layers. The picture in
E is taken at lower magnification than that in E to show that the staining pattern is consistent over an area of tissue.
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Figure 4 Klymenko et al.
Figure 4. SRSF3 is required for L1 protein expression. (A) Western blot analysis of SR protein depletion for the
experiment shown in (E). SRSF1, 2, 3 and 7 were detected with specific antibodies. SRSF1, 2 and 5 were detected
with Mab104. The panel showing SRSF2 depletion was probed with Mab104. Only the area of the blot showing
SRSF2 and SRSF1 bands is shown. SRSF2 is the upper band.  U, undifferentiated, D, differentiated NIKS16 cells.
Cntrl, cells transfected with a control siRNA. (B) SRSF3 depletion results in reduced L1 protein levels. Western blot
analysis of L1 protein in, differentiated keratinocytes (D) with the various SR proteins depleted. (U), undifferentiated
NIKS16 cell extracts were analysed as a negative control for L1 protein expression. Cntrl, cells transfected with a
control siRNA. Involucrin was detected as a control for differentiated epithelial cells. GAPDH was detected as a
protein loading control. (C) Quantification of levels of L1 protein in NIK16 keratinocytes transfected with a control
siRNA (cntrl) or siRNAs against each of the SR proteins shown on the X-axis. U, undifferentiated keratinocytes D,
differentiated keratinocytes. The graph shows the mean and standard deviation from the mean from three separate
experiments. Values were calculated relative to GAPDH levels. P-value was calculated using a student’s T-test.
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Figure 5 SRSF3 controls L1 protein levels in W12E cells. (A) Western blot analysis of SRSF1 and 3 protein
depletion by siRNA in U, undifferentiated and D, differentiated W12E cells. Much higher levels of SRSF1 and SRSF3
were detected in differentiated W12E cells as expected [24]. L1 protein was not detected in U, undifferentiated W12E
cells even with SRSF1 or SRSF3 depletion. L1 protein was detected in D, differentiating W12E cells but levels were 
educed in the cells treated with siRNA against SRSF3. Cntrl, cells transfected with a control siRNA. Involucrin was
detected as a control for differentiated epithelial cells. GAPDH was detected as a protein loading control. This
experiment was carried out five times and very similar data were obtained each time. (B) Western blot quantification
of levels of L1 protein in differentiated W12E keratinocytes transfected with a control siRNA (cntrl) or siRNAs against
SRSF1 or SRSF3. The graph shows the mean and standard deviation from the mean from three separate experiments.
Values were calculated relative to GAPDH levels. P-value was calculated using a student’s T-test. (C) Undifferentiated
NIKS16 cells were transfected with vector control (Cntrl) or a plasmid encoding the SRSF3 protein (SRSF3 transfect).
Differentiated NIK16 cell extracts (DNIKS16) were probed as a control for L1 expression.  GAPDH was used as a
loading control. Involucrin was detected as a marker of epithelial differentiation. The level of involucrin was so high in
the differentiated compared to the undifferentiated NIK16 cell extracts that the blot was bleached out in lane 1.
The experiment was repeated twice and very similar data were obtained each time.
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Figure 6 SRSF3 controls levels of the E4^L1 mRNA. (A) Schematic diagram of the HPV16 genome. Open reading
frames 6re represented with light grey boxes with the gene names beneath. Promoters are indicated with
arrowheads. Polyadenylation sites are indicated with downward arrows (Poly(A)E/L). The major late mRNA splicing
events with the open reading frames (dark grey boxes) and introns (dark grey lines) are indicated below the
genome map. Each mRNA is shown truncated at the 5’ end to indicated the presence of several possible initiation
sites for transcription of these mRNAs [10]. The open reading frames in each mRNA are indicated to the right hand
side. (B) Western blot analysis of levels of SRSF1 and SRSF3 in NIKS16 cells following siRNA knock down.
siSRSF1, siRNA against SRSF1. siSRSF3, siRNA against SRSF3. siCntrl, control siRNA. GAPDH was detected
as a protein loading control. (C) RT-PCR detection of HPV late mRNAs type B (upper gel) or type C (lower gel) in
cDNA synthesized from RNA isolated from the same cell populations analysed in (B). Cntrl, control siRNA. SRSF1,
siRNA against SRSF1. SRSF3, siRNA against SRSF3. RT, reverse transcriptase. M, 1Kb DNA marker ladder.
GAPDH was amplified as an internal control for RNA concentrations. (D) Relative levels of E4^L1 spliced mRNA B
compared to GAPDH mRNA determined by qPCR. The mean and standard deviation from the mean are shown
from three separate experiments. (E) Relative levels of unspliced L2L1 mRNAs C compared to GAPDH mRNA
determined by qPCR. The mean and standard deviation from the mean are shown from three separate experiments.
P-values were calculated using a student’s T-test.
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